Tim Boreham: Meet the ASX team behind the teams

While 36 nervous players line up (or line up, depending on when you’re reading this) on the wide green of the MCG for the AFL grand finale, it’s worth mentioning the myriad of feats that allow sportsmen to jump further in. high and kicking further, while also healing their wounds.

Unlike in the United States or the United Kingdom, it is not possible for fans to “own” a football team, with the exception of the National Rugby League club listed on the ASX Brisbane Broncos (ASX: BBL). With the top 20 holders (including News Corporation at 68%) accounting for 95% of the register, liquidity is tiny.

For the latest biotechnology news, sign up for Stockhead’s daily newsletters for free here

Australian Football League clubs North Melbourne and this year’s grand final contestant Sydney Swans dabbled in public ownership in the 1980s, with disappointing results.

Elsewhere on the stock exchange, there is no shortage of titles exposed to the behind-the-scenes activities that allow players – and sportsmen in general – to provide a knockout performance.

By the way, let’s start with Cogstate (ASX: CGS), who developed a more reliable concussion test than the old one: “What day of the week is it?” routine.

A must-have device in a club doctor’s toolbox, the Cogstate test is a screen-based tool that can provide a result within 15 minutes.

Footy codes have several billion reasons to take concussion more seriously, given the scale of negligence payments in the United States.

Further refinement measurement, HitIQ (ASX: HIQ) listed in June last year on the back of its concussion detection analyzes, which are embedded in a mouthguard.

HitIQ has concussion detection and management ties to the AFL, as well as offshore codes including ice hockey, lacrosse, American football, and mixed martial arts.

Visit Stockhead, where uppercase ASX is big business

The company is also the “exclusive partner for concussion management technology” for the Rugby World Cup, which kicks off on 15 October.

In the past, a decent performance was known as “kicking a bag” or “getting skin poisoning,” but people a Catapult Group (ASX: CAT)they are more scientific.

Catapult was one of the first to introduce wearable devices that capture player performance data to allow coaches to view it live or after the match.

Having enrolled Hawthorn Football Club as its first client in 2007, Catapult has a client base of 3,400 professional sports teams across 40 sports.

When a player is cruelly struck with a knee or hip injury, paramedics will take the “green whistle”, which is not a reference to the referee’s tool of trade but a device that dispenses the temporary pain reliever Penthrox.

Medical Developments (ASX: MVP) owns the rights to Penthrox, a reformulation of methoxiflurane that has been used by the ambulance services here since 1975.

Penthrox is now sold in dozens of countries, the United States is a notable omission.

However, the Food & Drug Administration recently cleared a clinical trial that could pave the way for approval in the United States.

While sport is meant to nourish the body and soul, it is not exactly the case with the knees, shoulders and ankles. Paradigm Pharmaceuticals (ASX: PAR) is raising the hopes of retired footballers with its anti-inflammatory lead compound for treating knees and joints, pentosan sodium polysulfate (PPS).

Although the PPS has yet to be approved, it hasn’t stopped dozens of former AFL players from using the drug under a special access scheme.

The company completed a capital raise of approximately $ 50 million this month, ahead of a phase 3 global study in osteoarthritis that will determine whether the drug can be approved. As with game plans, the best medical devices are usually simple ones.

To take Renamed (ASX: RNO)who developed Turbine, a simple clip-like device that attaches to the nose and dilates the nostril, allowing athletes (typically cyclists) to inhale more air and fewer banned substances.

While Turbine remains on sale, Rhinomed has since found greater fortunes with variant devices for sleep apnea and Covid tests.

Not all of these titles have caught on – Hitiq is worth a modest $ 6 million – but that’s not over until the final siren.

This story does not constitute financial product advice. You should consider getting independent advice before making any financial decisions.

Get more Tim Boreham’s wisdom on stockhead.com.au


Get the latest Stockhead news delivered to your inbox for free. Click here

Originally released as Tim Boreham: Meet the ASX Team Behind the Teams